COPD Exacerbation

On this page

Quick Reference

RxDrug of choiceSABA (Salbutamol) + SAMA (Ipratropium) + Systemic Corticosteroids (Prednisone 40 mg)

AltAlternativesNebulized Budesonide 2 mg (if systemic steroids contraindicated); Macrolides or Amoxicillin/Clavulanate (for antibiotics)

⊘AvoidHigh-flow oxygen without monitoring (risk of hypercapnic respiratory failure); long-term steroid tapers (>5 days)

DxTest of choiceArterial Blood Gas (ABG) for severity; POCUS for differential diagnosis

ScKey scoreAnthonisen Criteria (Symptom-based); GOLD Severity Classification (Intervention-based)

→When to referpH <7.25, altered mental status, hemodynamic instability, or failure of NIV

Treat AECOPD with 5 days of prednisone, targeted antibiotics for purulent sputum, and NIV for respiratory acidosis, while maintaining SpO2 at 88-92%.

An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a critical clinical event characterized by a sustained worsening of respiratory symptoms—specifically dyspnea, cough, and sputum production—that necessitates a change in regular medication. These episodes are not merely temporary setbacks but are major drivers of disease progression, permanent lung function decline, and increased mortality. Management focuses on rapid reversal of airflow obstruction using bronchodilators, reducing systemic inflammation with short-course corticosteroids, and treating infectious triggers with targeted antibiotics.

Overview and Recommendations

Background

•Define an acute exacerbation (AECOPD) as a clinical event characterized by increased , cough, or sputum production beyond daily variations that requires a change in therapy.
•Recognize the primary triggers, which include respiratory viruses (Rhinovirus is most common, followed by Influenza and RSV), bacterial pathogens (Nontypeable Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis), and environmental pollutants.
•Understand the clinical impact of exacerbations, which drive the "multidimensional progression" of , often leading to a permanent loss of lung function and increased risk of future cardiovascular events for up to 6 months post-discharge.
•Classify exacerbations by severity based on the required intervention: Mild (treated with short-acting bronchodilators only), Moderate (requires oral corticosteroids and/or antibiotics), and Severe (requires hospitalization or emergency department evaluation).
•Identify high-risk phenotypes, such as patients with frequent exacerbations (≥2 per year), those with underlying frailty, or those with comorbid , all of whom face significantly higher mortality and readmission rates.

Evaluation

•Suspect AECOPD in any patient with known COPD presenting with the Anthonisen triad: increased dyspnea, increased sputum volume, and increased sputum purulence.
•Ask about the prodromal phase, specifically looking for subtle increases in cough or changes in sputum color that preceded the acute escalation of symptoms.
•Examine the patient for signs of respiratory distress, including accessory muscle use, paradoxical chest wall movement, and the presence of new wheezing or crackles on auscultation.
•Obtain immediate and target an initial saturation of 88–92% while awaiting further diagnostic testing.
•Order an Arterial Blood Gas (ABG) for any patient with SpO2 <92%, significant respiratory distress, or altered mental status to identify acute (pH <7.35 and PaCO2 >45 mmHg).
•Perform Point-of-Care Ultrasound (POCUS) using the EMERALD-US protocol to rapidly differentiate AECOPD from (look for B-lines) and pneumonia (look for consolidation).
•Rule out pulmonary embolism (PE) in patients with unexplained exacerbations, pleuritic chest pain, or dyspnea out of proportion to clinical signs, using D-dimer or CT (CTPA).
•Order a Chest X-ray (CXR) to screen for concomitant pneumonia, which occurs in approximately 48.7% of hospitalized AECOPD cases, or to rule out a .
•Check admission blood eosinophil counts; levels <100 cells/µL are associated with higher inpatient mortality and may suggest a lower likelihood of response to corticosteroids.
•Utilize serum procalcitonin (PCT) to guide antibiotic therapy; consider withholding antibiotics if PCT <0.1 ng/mL and strongly encourage them if PCT >0.25 ng/mL.
•Obtain an ECG and NT-proBNP to screen for acute cardiovascular events (CVEs), such as new-onset or left ventricular dysfunction, which are common during the acute phase.
•Apply the 5-item CERT checklist to confirm the diagnosis; a score of ≥2 moderate-to-severe items is considered positive for an exacerbation.

Management

•Administer short-acting β2-agonists (SABA) such as Salbutamol 2.5–5 mg via nebulization every 1–4 hours as needed for rapid bronchodilation.
•Combine SABA with a short-acting muscarinic antagonist (SAMA) like Ipratropium bromide 0.5 mg every 4–6 hours, as the combination is superior to monotherapy in reducing hospitalizations.
•Prescribe systemic corticosteroids to improve FEV1 and shorten hospital stay; the standard regimen is Prednisone 40 mg orally once daily for exactly 5 days.
•Consider nebulized Budesonide 2 mg every 6 hours as an alternative to systemic steroids if the patient has contraindications to oral/IV glucocorticoids or to reduce systemic side effects.
•Initiate empiric antibiotics for patients with increased sputum purulence or those requiring mechanical ventilation; first-line options include Amoxicillin/Clavulanate 875/125 mg BID or Azithromycin 500 mg on day 1 followed by 250 mg daily for 5 days.
•Maintain controlled oxygen therapy to a target SpO2 of 88–92%; avoid high-concentration oxygen which can worsen hypercapnia via the Haldane effect and ventilation-perfusion mismatch.
•Initiate Non-Invasive Ventilation (NIV) for patients with respiratory acidosis (pH <7.35) or persistent dyspnea despite medical therapy; start with BiPAP at IPAP 10–12 cm H2O and EPAP 4–5 cm H2O.
•Monitor ABG within 1–2 hours of starting NIV; if pH remains <7.30 and the patient is not improving, escalate to intensive care for possible .
•Utilize High-Flow Nasal Oxygen (HFNO) as a comfortable alternative to NIV in patients with mild-to-moderate hypercapnic respiratory failure (pH 7.25–7.35).
•Avoid the use of morphine for anxiety in patients with concomitant COPD and heart failure; midazolam is preferred if sedation is absolutely necessary for NIV tolerance.
•Transition the patient to long-acting bronchodilators, such as Tiotropium 18 µg daily or Salmeterol 50 µg BID, before hospital discharge to prevent early recurrence.
•Implement early mobilization and rehabilitation, such as using a pedal exerciser during the hospital stay, to improve muscle strength and balance.
•Provide nutritional support for malnourished patients, specifically high-protein supplements containing beta-hydroxy-beta-methylbutyrate (HP-HMB) twice daily.
•Refer patients with significant functional impairment or slow gait speed to rapid access rehabilitation (RAR) programs upon discharge.
•Ensure a follow-up appointment within 1–2 weeks of discharge to assess the Assessment Test (CAT) score and adjust maintenance therapy.

Board Review — High Yield

•Anthonisen Criteria — Diagnosis requires increased dyspnea, sputum volume, and sputum purulence.
•Target SpO2 — 88–92% is the goal to prevent worsening hypercapnia and acidosis.
•REDUCE Trial — Established that 5 days of systemic corticosteroids is non-inferior to 14 days for AECOPD.
•Eosinophils — Low admission counts (<100 cells/µL) are a marker of poor prognosis and reduced steroid response.
•NIV Indications — pH <7.35 and PaCO2 >45 mmHg; it reduces the need for intubation and decreases mortality.
•Rhinovirus — The most frequently identified viral trigger for acute exacerbations.
•Procalcitonin — A validated tool to reduce unnecessary antibiotic use; withhold if <0.1 ng/mL.
•Pulmonary Embolism — Found in up to 25% of patients hospitalized with unexplained COPD exacerbations.

Deep Dive — Evidence Details

Etiology and Triggering Factors

▸Respiratory viruses (Rhinovirus, RSV, Influenza) are detected in over 40% of severe AECOPD cases.
▸Bacterial pathogens like H. influenzae and S. pneumoniae are found in roughly 50% of severe exacerbations.
▸Sputum purulence and fever are strong predictors of bacterial involvement.
▸RSV-ARI in older adults increases the long-term risk of subsequent COPD exacerbations.
▸Pneumonia in COPD (PCOPD) is a distinct, more severe entity than simple AECOPD, characterized by higher inflammatory markers.
▸Influenza vaccination significantly reduces AECOPD-related hospitalizations.

CP Clinical Pearl: Increased sputum purulence and volume are the most reliable clinical indicators of bacterial infection in AECOPD, warranting antibiotic consideration [117].

Dx Diagnostic Essentials: Urinary pneumococcal antigen testing is a useful adjunct in AECOPD, identifying S. pneumoniae in approximately 17-20% of hospitalized cases [14].

! Warning: COPD patients with concomitant pneumonia (consolidation on X-ray) have a worse prognosis and higher systemic inflammation than those with simple exacerbations [120].

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are primarily triggered by respiratory infections, which account for a significant proportion of hospitalizations and morbidity. These triggers are broadly categorized into viral, bacterial, and environmental factors, often occurring in combination.

Viral Pathogens

Respiratory viruses are a major driver of AECOPD, particularly in community-managed cases and severe hospitalizations. Studies using multiplex polymerase chain reaction (PCR) have identified viral infections in approximately 41.2% of severe AECOPD events ^[29]^D. The most frequently isolated virus is Rhinovirus, followed by Respiratory Syncytial Virus (RSV) and Influenza ^[29]^D. Influenza infection is a critical cause of AECOPD; predictors of influenza PCR positivity include specific clinical features, though these can overlap with other triggers ^[26]^D. RSV-related acute respiratory illnesses (RSV-ARI) are associated with long-term adverse outcomes, including an increased risk of subsequent COPD exacerbations and readmissions compared to controls ^[114]. Furthermore, the COVID-19 pandemic highlighted the impact of viral transmission; while infection control measures reduced the incidence of some respiratory triggers, COVID-19 itself emerged as a distinct cause of acute respiratory failure (ARF) in COPD patients, often requiring specialized respiratory support ^[9]^[119].

Bacterial Pathogens

Bacterial involvement is established in approximately 50% of severe AECOPD cases ^[117]. In cigarette smokers, the most common bacterial pathogens identified include Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis ^[10]. Streptococcus pneumoniae is particularly prevalent, with urinary pneumococcal antigen tests returning positive in 17.1% of patients hospitalized for AECOPD ^[14]. Bacterial etiology is more likely in patients presenting with increased sputum purulence and hyperthermia ^[117]. In Asian multicenter surveillance, antimicrobial resistance remains a significant concern among these common isolates ^[116]. Early intervention with targeted antibiotics, such as garenoxacin, has shown clinical benefits in bacterial infection-induced exacerbations ^[118].

Concomitant Pneumonia and ARDS

Pneumonia is considered a distinct comorbidity that complicates COPD rather than a simple infectious exacerbation. Patients with COPD and concomitant pneumonia (PCOPD) typically exhibit more severe clinical presentations, including higher levels of C-reactive protein (CRP) and longer hospital stays compared to those with AECOPD alone ^[120]. An infectious etiology can be established in approximately 48.7% of AECOPD cases with concomitant pneumonia ^[12]. Furthermore, COPD patients are at risk for Acute Respiratory Distress Syndrome (ARDS); in urban hospital settings, HIV-1 infection has been noted as a complicating factor in patients developing ARDS, although its specific prevalence in the COPD subgroup varies ^[115].

Environmental and Systemic Factors

Smoking remains the primary underlying risk factor, as it alters the epithelial cell surface and increases susceptibility to respiratory tract infections ^[10]. Chronic bronchitis (CB) serves as a chronic inflammatory state that not only predisposes patients to AECOPD but also increases the risk of systemic complications such as ischemic stroke ^[121]. Acute respiratory failure (ARF) resulting from AECOPD is a major driver of healthcare costs and prehospital emergency medical service (EMS) utilization ^[11]^[8].

Preventive and Diagnostic Considerations

Preventive measures, specifically influenza vaccination, have been shown to significantly reduce the frequency of outpatient visits and hospitalizations for AECOPD ^[15]. However, some studies suggest that while vaccination is protective against respiratory decline, it may not fully mitigate the increased risk of ischemic stroke associated with acute infections in patients with chronic bronchitis ^[121]. For diagnosis, emerging technologies like the electronic nose (e-nose) are being evaluated for their ability to distinguish between viral and bacterial triggers by analyzing volatile organic compounds in exhaled breath ^[13].

Common Pathogens in AECOPD

Pathogen Type	Common Organisms	Evidence Level
Viral	Rhinovirus, RSV, Influenza, SARS-CoV-2	1b, 3b ^[9]^[29]^D^[114]
Bacterial	H. influenzae, S. pneumoniae, M. catarrhalis, S. aureus	2b, 3b ^[10]^[14]^[116]
Atypical	Mycoplasma pneumoniae, Chlamydia pneumoniae	4 ^[22]

Diagnosis and Workup

▸Diagnosis is primarily clinical, supported by changes in lung acoustics and patient-reported checklists like CERT.
▸Blood eosinophil counts < 0.05 x 10⁹/L at admission are associated with higher mortality.
▸POCUS offers 100% sensitivity for pleural effusion and interstitial lung disease in the emergency setting.
▸Respiratory viruses, particularly influenza, are present in over 40% of severe exacerbations.
▸Procalcitonin-guided protocols are noninferior to standard antibiotic therapy in ICU-admitted AECOPD patients.
▸Functional markers like gait speed and frailty status are significant predictors of post-discharge outcomes.

Dx Diagnostic Essentials: Arterial blood gas (ABG) remains the gold standard for diagnosing respiratory acidosis and guiding the need for non-invasive ventilation (NIV) in the prehospital and hospital settings [123].

CP Clinical Pearl: Gait speed at discharge is a simple, low-cost functional parameter that predicts readmission risk more effectively than many complex severity scores [50].

! Warning: Clinicians using AI-assisted diagnostic tools should be aware that systematic model biases can lead to diagnostic errors unless accompanied by transparent image-based explanations [32].

Clinical Presentation and Initial Assessment

The diagnosis of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is primarily clinical, characterized by a worsening of the patient's baseline dyspnea, cough, and/or sputum production. Physical examination often reveals changes in lung acoustics; computerized analysis shows that adventitious respiratory sounds (ARS) are significantly altered during the acute phase compared to stable disease or healthy controls ^[56]^D. Patients with AECOPD exhibit increased airway obstruction and mucus, which correlate with these acoustic changes ^[56]^D. Early recognition is critical, and patient-centered tools like the five-item CERT checklist (positive if ≥ 2 items are rated moderate/severe) have shown accuracy comparable to the 14-item EXACT diary for discriminating exacerbation days ^[43]^D.

Laboratory Investigations and Biomarkers

Standard workup includes inflammatory and hematological markers. Recent evidence suggests that clot microstructure, measured by fractal dimension (df), is altered during AECOPD, indicating a higher thrombogenic potential compared to stable COPD ^[44]^D.

Eosinophils: Admission blood eosinophil counts are prognostic; a count of < 0.05 x 10⁹/L is associated with increased inpatient mortality and higher 1-year mortality rates ^[47]^D.
Procalcitonin (PCT): In the ICU setting, using a PCT-guided algorithm (with predefined cutoffs for starting or stopping therapy) to manage antibiotic initiation has been shown to be noninferior to standard care regarding 3-month mortality ^[35].
Viral Screening: Respiratory viruses are detected in approximately 41.2% of severe AECOPD cases ^[29]^D. Influenza is a major driver; predictors of influenza PCR positivity include higher body temperature, shorter duration of symptoms before admission, and lower malignancy rates ^[26]^D.

Imaging and Point-of-Care Ultrasound (POCUS)

While chest X-ray remains a standard first-line investigation, Point-of-Care Ultrasound (POCUS) has demonstrated high diagnostic utility. POCUS shows 100% sensitivity and specificity for diagnosing pleural effusion and interstitial lung disease in dyspneic patients, and 92.3% sensitivity for pneumonia, often providing faster results than traditional radiography ^[45]^D. Artificial intelligence (AI) is increasingly used to support diagnostic accuracy in hospitalized patients, though clinicians must be wary of systematic biases in AI models that can worsen accuracy if not mitigated by model explanations ^[32].

Physiological and Functional Assessment

Arterial blood gas (ABG) analysis is essential for identifying respiratory acidosis (pH < 7.30 and PaCO2 > 6.0 kPa), which defines severe exacerbations requiring advanced respiratory support ^[123]. Functional markers also provide prognostic value:

Gait Speed: A simple gait speed test at hospital discharge is a strong predictor of death or readmission in survivors of acute hypercapnic respiratory failure ^[50]^D.
Frailty: Frailty is an independent predictor of in-hospital mortality in older patients with AECOPD ^[39].
Sarcopenia: Acute sarcopenia (dynamic loss of muscle strength or quantity) can be assessed via handgrip strength and ultrasound of the bilateral anterior thigh thickness (BATT) during the acute event ^[46]^D.

Differential Diagnosis and Comorbidities

It is vital to differentiate AECOPD from acute heart failure (HF). The Get With the Guidelines-Heart Failure (GWTG-HF) risk score, which utilizes seven variables, can predict mortality risk in patients with comorbid HF ^[53]^D. Additionally, for patients traveling to high altitudes, dexamethasone (8 mg/d) has been shown to reduce the incidence of acute mountain sickness and altitude-related adverse health effects in those with GOLD grade 1-2 COPD ^[34].

Diagnostic and Prognostic Markers in AECOPD

Marker	Threshold/Finding	Clinical Significance
Blood Eosinophils	< 0.05 x 10⁹/L	Increased inpatient and 1-year mortality ^[47]^D
pH / PaCO2	pH < 7.30 / PaCO2 > 6.0 kPa	Definition of respiratory acidosis for NIV ^[123]
CERT Checklist	≥ 2 moderate/severe items	Accurate for early AECOPD recognition ^[43]^D
Viral PCR	Positive in 41.2% of cases	Rhinovirus and Influenza are common ^[29]^D
POCUS	100% Sensitivity	Superior for pleural effusion/interstitial disease ^[45]^D

Differential Diagnosis

▸Acute heart failure is present in over 35% of patients hospitalized for acute decompensated heart failure who also have COPD.
▸Lung ultrasound (POCUS) and NT-proBNP are superior to clinical assessment for differentiating AHF from AECOPD.
▸Pulmonary embolism prevalence is approximately 16.1% in unexplained COPD exacerbations.
▸CRP and procalcitonin are significantly higher in pneumonia-associated exacerbations than in simple AECOPD.
▸Midazolam is preferred over morphine for anxiety in patients with comorbid ACPE and COPD.
▸Malnourished older adults with AECOPD benefit from high-protein nutritional supplementation to reduce mortality.

Dx Diagnostic Essentials: In unexplained AECOPD, the prevalence of pulmonary embolism is 16.1%. Clinicians should maintain a high index of suspicion and consider CT pulmonary angiography (CTPA) [57].

CP Clinical Pearl: Bedside lung ultrasound (POCUS) provides 100% sensitivity and specificity for identifying pleural effusions and interstitial lung disease in the emergency department [45].

! Warning: Morphine use in patients with acute cardiogenic pulmonary edema and COPD is associated with more serious adverse events compared to midazolam [58].

The differential diagnosis of a COPD exacerbation (AECOPD) is broad, as many acute respiratory and cardiovascular conditions present with similar symptoms of dyspnea, cough, and sputum production. Accurate differentiation is critical, as comorbid conditions like heart failure and pulmonary embolism significantly impact mortality and readmission rates ^[61]^[124].

Cardiovascular Mimics and Comorbidities

Acute heart failure (AHF) and acute cardiogenic pulmonary edema (ACPE) are the most frequent mimics of AECOPD. Approximately 35.9% of patients hospitalized with acute decompensated heart failure have a history of COPD ^[124]. Differentiating these is challenging because COPD patients often present with a worse cardiovascular profile, including higher rates of atrial fibrillation, diabetes, and hypertension ^[125]^C.

Diagnostic Tools: Bedside lung ultrasound (POCUS) for the 'comet-tail' sign (B-lines) combined with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels significantly improves diagnostic accuracy over clinical assessment alone ^[60]. POCUS has demonstrated 100% sensitivity and specificity for identifying pleural effusions and interstitial lung disease in the emergency setting ^[45]^D.
Biomarkers: Circulating microRNAs (miRNAs) have shown potential in differentiation; levels are typically decreased in AHF but remain unchanged in AECOPD compared to controls ^[127].
Management Considerations: In patients with ACPE and COPD, the use of midazolam for anxiety is associated with fewer serious adverse events compared to morphine ^[58]. Furthermore, while beta-blockers are often underused in COPD, they do not appear to increase in-hospital mortality or mechanical ventilation risk during an exacerbation in patients with underlying heart disease ^[126].

Pulmonary Embolism (PE)

Pulmonary embolism is a frequent and often overlooked cause of unexplained AECOPD. The prevalence of PE in patients with unexplained exacerbations is approximately 16.1% ^[57].

Localization: Most emboli in this population are located in the main pulmonary arteries (3.3%), lobar arteries (6.8%), or segmental arteries (9.0%) ^[57].
Clinical Impact: PE in the setting of AECOPD is associated with a higher risk of mortality and longer intensive care unit (ICU) stays ^[129]. Long-term follow-up of PE survivors shows that 18.3% to 21.9% continue to have abnormal functional capacity (6-minute walk distance) at 12 months ^[71]^D.

Infectious Etiologies

Pneumonia often triggers or mimics AECOPD. Differentiating community-acquired pneumonia (CAP) from a simple exacerbation is vital for antibiotic stewardship.

Inflammatory Markers: C-reactive protein (CRP), procalcitonin (PCT), and neopterin (NPT) are used to distinguish these states. CRP and PCT levels are significantly higher in patients with CAP+COPD compared to those with AECOPD alone ^[128].
Viral Triggers: Respiratory Syncytial Virus (RSV) is a significant cause of hospitalized acute respiratory illness in older adults, leading to long-term risks of subsequent COPD exacerbations and heart failure hospitalizations ^[114].

Diagnostic Challenges and AI Support

Diagnostic accuracy in the hospital setting remains a concern. Recent studies suggest that while AI models can support clinicians in diagnosing complex cases, systematically biased AI can worsen clinician accuracy unless mitigated by image-based explanations ^[32].

Nutritional and Geriatric Considerations

In older adults (≥65 years) hospitalized for AECOPD, malnutrition is a major driver of poor outcomes. Specialized high-protein oral nutritional supplements containing beta-hydroxy-beta-methylbutyrate (HP-HMB) have been shown to reduce post-discharge mortality ^[59]. Additionally, elderly patients are at high risk for potentially inappropriate medications (PIMs) at discharge, which can complicate the clinical course ^[91]^D.

Differential Diagnosis of Acute Dyspnea in COPD Patients

Condition	Key Diagnostic Findings	Evidence Level
Acute Heart Failure	Elevated NT-proBNP, B-lines on POCUS, decreased miRNAs	2b, 3b ^[60]^[127]
Pulmonary Embolism	Filling defects on CTPA, unexplained exacerbation	2a, 3b ^[57]^[129]
Pneumonia	High CRP/PCT, consolidations on POCUS/CXR	3b ^[128]^[45]^D
RSV Infection	Viral PCR, associated with long-term HHF risk	3b ^[114]

Management: Pharmacological Therapy

▸Short-term systemic corticosteroid therapy (5 days) is non-inferior to conventional 14-day courses for AECOPD.
▸Procalcitonin-guided protocols (threshold <0.1 ng/ml) effectively reduce antibiotic exposure without compromising safety, even in ICU settings.
▸Vibrating mesh nebulizers provide superior drug deposition compared to jet nebulizers during non-invasive ventilation.
▸Nebulized budesonide is a clinically effective alternative to systemic methylprednisolone with fewer side effects.
▸Roflumilast reduces exacerbation frequency when added to long-acting bronchodilator regimens in patients with chronic bronchitis.
▸High-protein nutritional supplementation (HP-HMB) reduces post-discharge mortality in malnourished COPD patients.

CP Clinical Pearl: Vibrating mesh nebulizers (VMN) are more effective than jet nebulizers for bronchodilator delivery during NIV, ensuring better pulmonary deposition of salbutamol and ipratropium [33].

! Warning: Patients with low procalcitonin (<0.1 ng/ml) do not benefit from antibiotic therapy, and its avoidance does not negatively impact treatment success [75].

HY High Yield: Poor sleep quality (PSQI >5) in stable COPD patients is a significant predictor of the time to first exacerbation and overall exacerbation rate [77].

Pharmacological management of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) focuses on rapid bronchodilation, reduction of airway inflammation, and targeted antimicrobial therapy. Short-acting β2-agonists (SABA) remain the cornerstone of emergency department (ED) treatment ^[73]. While SABA monotherapy is standard, the addition of short-acting anticholinergics like ipratropium bromide (IB) to terbutaline has been evaluated in hypercapnic AECOPD requiring non-invasive ventilation (NIV); however, evidence suggests this combination may not significantly reduce hospital or intensive care unit (ICU) admission rates compared to terbutaline alone ^[73].

Bronchodilator Delivery and Novel Agents

The method of aerosol delivery during NIV significantly impacts pulmonary deposition. Vibrating mesh nebulizers (VMN) have demonstrated superior effectiveness compared to jet nebulizers (JN), providing higher radiolabeled aerosol deposition across all lung regions in subjects with moderate to severe COPD ^[33]. Beyond short-acting agents, long-acting β2-agonists (LABAs) such as indacaterol have been investigated for acute use. Indacaterol (150 μg or 300 μg) has shown a fast onset of action and sustained 24-hour bronchodilation without causing the transient decrease in PaO2 often seen with other β2-agonists, making it a potentially safe option during acute exacerbations ^[79]^[84]. Furthermore, the efficacy of long-acting bronchodilators like tiotropium and salmeterol in preventing future exacerbations does not appear to be significantly influenced by ADRB2 polymorphisms (Arg16Gly and Gln27Glu) ^[78]. Tiotropium, specifically, has been shown to significantly increase the time to first exacerbation and reduce overall exacerbation rates in pooled analyses ^[80].

Corticosteroid Therapy

Systemic corticosteroids are recommended to improve clinical outcomes, though the optimal duration is a subject of refinement. The REDUCE trial established that a 5-day short-term course of systemic glucocorticoids is non-inferior to the conventional 14-day treatment regarding clinical outcomes and re-exacerbation rates ^[81]. In critically ill patients, retrospective data also support that short-course therapy (≤5 days) does not increase treatment failure compared to extended tapers ^[101]^D. For patients at risk of systemic side effects, nebulized budesonide has emerged as a viable alternative to intravenous methylprednisolone, showing similar clinical efficacy in improving lung function and symptoms while potentially reducing the risk of systemic adverse events ^[74]. In specific environmental contexts, such as high-altitude travel (3,100 m), dexamethasone (8 mg/d) has been shown to prevent altitude-related adverse health effects in patients with COPD ^[34].

Antibiotics and Biomarker Guidance

Antibiotic use in AECOPD is increasingly guided by procalcitonin (PCT) levels to reduce unnecessary exposure. In patients with low serum PCT values (<0.1 ng/ml), studies indicate no significant benefit from antibiotic treatment regarding treatment success or exacerbation rates ^[75]. Even in severe AECOPD cases admitted to the ICU, PCT-guided algorithms (using a 5-day cutoff for initiation or cessation) are non-inferior to standard antibiotic therapy concerning 3-month mortality, while significantly reducing antibiotic duration ^[35].

Adjunctive and Maintenance Therapies

For patients with chronic bronchitis and frequent exacerbations, the phosphodiesterase-4 inhibitor roflumilast (500 μg) significantly reduces the risk of exacerbations when added to LABA therapy, regardless of prior inhaled corticosteroid use ^[130]. Nutritional and lifestyle factors also play a role in recovery; high-protein oral nutritional supplements containing beta-hydroxy-beta-methylbutyrate (HP-HMB) have been shown to reduce post-discharge mortality in malnourished hospitalized older adults with COPD ^[59]. Additionally, early bedside exercise interventions using pedal exercisers during hospitalization can improve muscle strength and balance in frail older patients ^[82]. While vitamin D and omega-3 fatty acids are under investigation for their role in reducing exacerbation risk, definitive trial results are pending ^[76]. Finally, clinicians should monitor sleep quality, as poor sleep (Pittsburgh Sleep Quality Index >5) is a strong predictor of future exacerbation risk ^[77].

Comparison of Corticosteroid Strategies in AECOPD

Strategy	Duration/Dose	Evidence Level	Clinical Outcome
Short-course Systemic	5 days	1b	Non-inferior to 14-day course ^[81]
Conventional Systemic	14 days	1b	Standard guideline recommendation ^[81]
Nebulized Budesonide	2 mg q12h	1b	Equivalent to IV methylprednisolone ^[74]
Dexamethasone	8 mg/d	1b	Prevents altitude-related adverse effects ^[34]

Management: Respiratory Support

▸NIV is the first-line treatment for AECOPD with respiratory acidosis (pH < 7.35).
▸HFNO is clinically noninferior to NIV for preventing intubation or death at 7 days.
▸Weak cough (SCSS ≤3) and APACHE II >19 are independent predictors of NIV failure.
▸Vibrating mesh nebulizers provide better drug deposition than jet nebulizers during NIV.
▸Gait speed at discharge predicts long-term survival following hypercapnic respiratory failure.

CP Clinical Pearl: Delayed response to NIV (persistent pH < 7.30 after 2 hours but clinical improvement within 48 hours) occurs in up to 53% of patients and does not necessarily mandate immediate intubation if the patient is otherwise stabilizing.

HY High Yield: HFNO is a cost-effective, noninferior alternative to NIV for AECOPD patients with respiratory acidosis, offering similar 7-day outcomes regarding intubation and mortality.

! Warning: National audit data shows a trend of increasing time-to-NIV, which may negatively impact mortality despite improvements in overall care standards.

Non-invasive Ventilation (NIV)

Non-invasive ventilation (NIV) remains the first-line respiratory support modality for acute exacerbations of COPD (AECOPD) complicated by acute hypercapnic respiratory failure (AHRF) ^[131]. While clinical practice sometimes deviates from trial data, real-world evidence confirms that NIV significantly improves outcomes when applied to patients with respiratory acidosis ^[131].

Timing and Models of Care

Timely initiation is critical; however, national audits indicate that while overall mortality for NIV-treated AECOPD has decreased (from 24.9% in 2008 to 16.8% in 2014), the proportion of patients receiving NIV within the recommended 60-minute window has also declined ^[97]^D. The optimal model of care remains debated. A prospective study comparing general ward (1:4 nurse ratio), high dependency unit (HDU, 1:2 ratio), and intensive care unit (ICU, 1:1 ratio) models found no significant difference in clinical outcomes or arterial blood gas (ABG) improvement when corrected for severity, suggesting ward-based NIV is feasible in experienced settings ^[100]^D. Even in rural medical wards, NIV has shown efficacy in treating severe acidosis (pH < 7.26) ^[132]^C. Furthermore, prehospital initiation of NIV guided by ABG analysis has been investigated to improve early physiological outcomes, though logistical constraints remain ^[123].

Predictors of Success and Failure

NIV failure, defined as the need for endotracheal intubation or death, occurs in approximately 6.5% to 21.1% of cases ^[102]^D^[105]^D. Key independent risk factors for failure include a weak cough (Semiquantitative Cough Strength Score ≤3), high disease severity (APACHE II >19), and malnutrition (total proteins ≤58 g/L) ^[105]^D. Anemia is also a significant predictor of poor short-term survival in patients requiring NIV ^[95]. While early response is typical, a "delayed responder" phenotype exists where patients show clinical improvement over 48 hours despite persistent acidosis (pH < 7.30) after the initial 2-hour trial; in these cases, continuing NIV may still result in success ^[102]^D.

Ventilation Modes and Adjuncts

Standard Pressure Support Ventilation (PSV) is the conventional mode, but Adaptive Support Ventilation (ASV) has been shown to be a feasible alternative with similar rates of NIV failure and patient comfort ^[38]. During NIV, the delivery of bronchodilators is more effective when using a vibrating mesh nebulizer (VMN) compared to a jet nebulizer, resulting in superior pulmonary deposition ^[33].

High-Flow Nasal Oxygen (HFNO)

High-flow nasal oxygen (or cannula, HFNC) is increasingly utilized as an alternative to NIV. The RENOVATE trial established that HFNO is noninferior to NIV regarding the rates of endotracheal intubation or death at 7 days for COPD patients with respiratory acidosis ^[9]. From an economic perspective, HFNO is considered a cost-minimizing strategy compared to NIV due to similar clinical outcomes and potentially lower resource intensity ^[8].

Physiologically, HFNC reduces the work of breathing. Research into interface design shows that both asymmetrical and symmetrical HFNC interfaces effectively reduce diaphragm and parasternal intercostal thickening fractions (TFdi and TFpi) at flow rates of 40 and 60 L/min, though comparative differences in muscle activity between the two interfaces are limited ^[122].

Functional Recovery and Prognosis

Respiratory support is only one component of management. For frail older patients hospitalized with AECOPD, adding an exercise intervention (such as a pedal exerciser) to standard care improves muscle strength and balance ^[82]. Functional markers are highly prognostic; for survivors of AHRF, gait speed at hospital discharge is a significant predictor of subsequent death or readmission ^[50]^D. In critically ill patients, the duration of corticosteroid therapy (short-course ≤5 days vs. extended) does not significantly alter the rate of respiratory support failure ^[101]^D.

Risk Factors for NIV Failure in AECOPD

Risk Factor	Threshold/Criteria	Odds Ratio (OR)
Weak Cough	SCSS ≤ 3	8.1
Disease Severity	APACHE II > 19	3.8
Malnutrition	Total Proteins ≤ 58 g/L	2.8
Anemia	Present at Admission	Associated with mortality

Prognosis and Long-term Outcomes

▸Frailty and cognitive impairment are major predictors of in-hospital mortality in older AECOPD patients.
▸High-flow nasal oxygen (HFNO) is noninferior to NIV for reducing intubation or death at 7 days.
▸Gait speed <0.8 m/s at discharge is a simple, effective predictor of readmission or death.
▸Suboptimal peak inspiratory flow (≤60 L/min) increases the risk of readmission due to poor inhaler technique.
▸Viral infections, particularly RSV and influenza, significantly worsen long-term COPD prognosis.
▸Short-course corticosteroid therapy (≤5 days) is as effective as longer tapers in ICU settings.

CP Clinical Pearl: A 'delayed response' to NIV (persistent acidosis at 2 hours) does not necessarily indicate failure; over 50% of such patients may still avoid intubation if clinical improvement is otherwise noted.

! Warning: Suboptimal peak inspiratory flow (≤60 L/min) is a common but often overlooked reason for treatment failure and readmission when using dry powder inhalers (DPIs).

HY High Yield: Frailty is a more potent independent predictor of in-hospital mortality in AECOPD than many traditional clinical scores.

Mortality and Readmission Risk

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with significant morbidity and high rates of post-discharge mortality and readmission ^[29]^D^[94]^D. In-hospital mortality is particularly elevated among older patients, with frailty serving as a critical independent predictor ^[39]^[112]^D. A prospective cohort study identified that frailty significantly increases the risk of in-hospital death, a relationship potentially mediated by laboratory indicators ^[39]. Among the 'oldest old' (aged ≥80 years), predictors of poor outcomes include cognitive impairment and functional status as measured by the Activities of Daily Living (ADL) Hierarchy scale ^[112]^D.

Long-term outcomes are also influenced by viral etiologies. Respiratory viral infections are detected in approximately 41.2% of severe AECOPD cases, with rhinovirus and influenza being the most common pathogens ^[29]^D. Furthermore, patients hospitalized for respiratory syncytial virus (RSV)-related acute respiratory illness face a higher cumulative incidence of subsequent COPD exacerbations and all-cause mortality compared to those without such infections ^[114].

Respiratory Support and Treatment Failure

The choice and timing of respiratory support are pivotal for prognosis. Non-invasive ventilation (NIV) remains the first-line modality for acute respiratory failure (ARF) in AECOPD ^[131]. While early response is typical, a 'delayed response'—defined as clinical improvement despite persistent severe respiratory acidosis (pH <7.30) after 2 hours of NIV—can still lead to successful outcomes in up to 53% of patients, provided NIV is continued under close monitoring ^[102]^D.

Recent evidence from the RENOVATE trial suggests that high-flow nasal oxygen (HFNO) is noninferior to NIV regarding the rates of endotracheal intubation or death at 7 days for patients with AECOPD and respiratory acidosis ^[9]. In the prehospital setting, initiating NIV guided by arterial blood gas analysis has been shown to improve early physiological outcomes compared to standard medical treatment ^[123]. Regarding ventilation modes, adaptive support ventilation (ASV) has demonstrated feasibility comparable to pressure support ventilation (PSV), with no significant differences in NIV failure rates or duration of mechanical ventilation ^[38].

Functional and Physiological Predictors

Functional parameters at the time of discharge are strong indicators of long-term stability. A gait speed of <0.8 m/s at hospital discharge is significantly associated with an increased risk of death or readmission among survivors of acute hypercapnic respiratory failure ^[50]^D. Additionally, physiological factors such as peak inspiratory flow (PIF) play a role in medication efficacy; a suboptimal PIF (≤60 L/min) is associated with higher rates of both 30-day and 90-day all-cause readmissions, likely due to inadequate drug delivery from dry powder inhalers ^[133].

Comorbidities and Systemic Factors

Comorbidities, particularly cardiovascular disease, heavily influence the prognosis of AECOPD. Chronic heart failure (CHF) frequently co-occurs with COPD; patients with both conditions have a higher burden of comorbidity and a significantly increased risk of respiratory-related readmissions compared to those with heart failure alone ^[61]. The Get With the Guidelines-Heart Failure (GWTG-HF) risk score, while designed for cardiac patients, highlights the prognostic impact of systemic markers like B-type natriuretic peptide (BNP) on post-discharge mortality ^[53]^D.

Environmental factors also pose risks; patients with GOLD grade 1 to 2 COPD traveling to high altitudes (3,100 m) are at risk for acute mountain sickness (AMS), though dexamethasone (8 mg/d) has been shown to reduce the incidence of altitude-related adverse health effects ^[34].

Healthcare Utilization and Policy Impact

Readmission rates are also influenced by systemic healthcare policies. Programs such as Medicare’s Hospital Readmissions Reduction Program (HRRP) have created financial incentives for hospitals to reduce 30-day readmissions for COPD, though the effectiveness of these incentives varies by hospital and condition-specific penalties ^[111]^D. In terms of pharmacological management, short-course corticosteroid tapers (≤5 days) have shown similar efficacy to extended courses in critically ill patients, with no significant difference in treatment failure rates ^[101]^D. Emerging therapies, such as the herbal combination HL301, are being investigated for reducing bronchitis severity scores in acute exacerbations, though their impact on long-term mortality remains to be established ^[109].

Prognostic Indicators in AECOPD

Indicator	Threshold/Value	Outcome Association
Gait Speed	<0.8 m/s	Increased death/readmission ^[50]^D
Peak Inspiratory Flow	≤60 L/min	Higher 30/90-day readmission ^[133]
pH (NIV Response)	<7.30 at 2h	'Delayed response' (may still succeed) ^[102]^D
Viral Infection	41.2% prevalence	Increased morbidity/mortality ^[29]^D
Corticosteroid Duration	≤5 days	Noninferior to >5 days ^[101]^D

Guidelines and Resources

▸AECOPD is characterized by irreversible airflow limitation and dynamic pulmonary hyperinflation, requiring specialized ventilation strategies [113].
▸Mechanical ventilation guidelines utilize a five-grade evidence system (A-E) to improve clinical results [113].
▸Antibiotics should be reserved for specific high-risk groups, including the elderly with co-morbidities and those with chronic cardiac or respiratory disease [87].
▸Diagnosis of AECOPD requires ruling out community-acquired pneumonia and distinguishing it from acute bronchitis [87].

HY High Yield: Mechanical ventilation for AECOPD must specifically address dynamic pulmonary hyperinflation, a feature that distinguishes it from other forms of respiratory failure [113].

! Warning: Antibiotics should not be used routinely for acute bronchitis unless the patient is elderly with co-morbidities or has underlying chronic cardiac/respiratory disease [87].

International and Regional Consensus Guidelines

The management of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is governed by evidence-based protocols designed to address the irreversible airflow limitation and dynamic pulmonary hyperinflation characteristic of the disease ^[113]. Guidelines emphasize the rational use of diagnostic and therapeutic resources to mitigate the high morbidity and mortality associated with the condition ^[87].

Mechanical Ventilation Strategies

According to the Chinese Society of Critical Care Medicine, mechanical ventilation strategies for AECOPD must be distinct from those used for other respiratory conditions due to the specific pathophysiology of COPD ^[113]. The consensus, developed using modified Delphi criteria, categorizes evidence into five grades (A through E) to optimize clinical outcomes ^[113]. Key considerations include:

Dynamic Hyperinflation: Ventilation must account for intrinsic positive end-expiratory pressure (PEEPi) to avoid barotrauma and hemodynamic instability ^[113].
Irreversible Airflow Limitation: Strategies focus on reducing the work of breathing while allowing sufficient expiratory time ^[113].

Management of Respiratory Infections and Antibiotic Stewardship

Inter-society consensus guidelines, such as those from the Argentine Society for Infectious Diseases, provide frameworks for managing COPD reactivations and distinguishing them from acute bronchitis (AB) ^[87].

Diagnostic Differentiation: AECOPD is defined as a sustained worsening of the patient's condition from the stable state, which is beyond normal day-to-day variations and is acute in onset ^[87]. This must be differentiated from AB, which occurs in patients without underlying pulmonary disease and is primarily viral ^[87].
Antibiotic Indications: While AB treatment is mainly symptomatic, antibiotics in the context of COPD reactivations or AB are specifically indicated for immune-compromised hosts, patients with chronic respiratory or cardiac diseases, and the elderly with co-morbidities ^[87].
Rational Resource Use: Guidelines aim to promote the rational use of diagnostic tools, ensuring that community-acquired pneumonia is ruled out before confirming a diagnosis of AB or AECOPD ^[87].

Evidence Grading and Clinical Focus

Guideline Focus	Key Recommendation	Evidence Grade/Source
Mechanical Ventilation	Address dynamic hyperinflation and airflow limitation	Chinese Society of Critical Care Medicine ^[113]
Antibiotic Use	Target immune-compromised, elderly, and those with co-morbidities	Argentine Society for Infectious Diseases ^[87]
Diagnostic Protocol	Rule out community-acquired pneumonia	Inter-society Consensus ^[87]

References

[1]
Effing TW, Kerstjens HAM, Monninkhof EM et al.. “Definitions of exacerbations: does it really matter in clinical trials on COPD?” Chest (2009). PMID: 19736196 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification
[2]
Gandhi A, Walsh EE, Formica MA et al.. “Factors associated with symptomatic rhinovirus infection in patients with COPD.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2012). PMID: 22999488 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[3]
Soler-Cataluña JJ, Martínez-García MÁ, Serra PC. “[Multidimensional impact of COPD exacerbations].” Archivos de bronconeumologia (2010). PMID: 21316556 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[4]
Huang T, Xu Z, Xu A et al.. “In-depth comparative pathogenome, virulome, and resistome analysis of an extensive drug resistant Ralstonia mannitolilytica strain isolated from blood.” Microbial pathogenesis (2024). PMID: 39306054 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[5]
Makris D, Bouros D. “COPD exacerbation: lost in translation.” BMC pulmonary medicine (2009). PMID: 19178701 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[6]
Su J, Liu HY, Tan XL et al.. “Sputum Bacterial and Fungal Dynamics during Exacerbations of Severe COPD.” PloS one (2015). PMID: 26147303 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[7]
Figliozzi S, Masci PG, Ahmadi N et al.. “Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.” European journal of clinical investigation (2020). PMID: 32726868 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, Diagnosis and Workup, Management: Pharmacological Therapy, Management: Respiratory Support, Prognosis and Long-term Outcomes
[8]
Beck da Silva Etges AP, Marcolino MAZ, Bianchini L et al.. “Economic analysis of high-flow nasal oxygen compared with noninvasive ventilation in patients with acute respiratory failure: results from the RENOVATE randomized clinical trial.” Respiratory medicine (2025). PMID: 40744283 ↗
L1bRCTCited in: Etiology and Triggering Factors, Management: Respiratory Support
[9]
Maia IS, Kawano-Dourado L, Tramujas L et al.. “High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial.” JAMA (2025). PMID: 39657981 ↗
L1bRCTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Management: Respiratory Support, Prognosis and Long-term Outcomes
[10]
Pasqua F, Biscione G, Crigna G et al.. “Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers.” Therapeutic advances in respiratory disease (2008). PMID: 19124373 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors
[11]
Cintora-Sanz AM, Horrillo-García C, Quesada-Cubo V et al.. “Prevalence and Economic Impact of Acute Respiratory Failure in the Prehospital Emergency Medical Service of the Madrid Community: Retrospective Cohort Study.” JMIR public health and surveillance (2025). PMID: 39819841 ↗
L2bCOHORTCited in: Etiology and Triggering Factors
[12]
Ko FW, Ip M, Chan PK et al.. “A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia.” Respiratory medicine (2008). PMID: 18573648 ↗
L2bCOHORTCited in: Etiology and Triggering Factors
[13]
van Geffen WH, Bruins M, Kerstjens HA. “Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study.” Journal of breath research (2016). PMID: 27310311 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors
[14]
Nishimura K, Nishimura T, Oga T. “Streptococcus pneumoniae urinary antigen test and acute exacerbations of chronic obstructive pulmonary disease.” COPD (2012). PMID: 22452423 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors
[15]
Menon B, Gurnani M, Aggarwal B. “Comparison of outpatient visits and hospitalisations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination.” International journal of clinical practice (2008). PMID: 18284444 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors
[16]
Clancy RL, Cripps AW. “An Oral Whole-Cell Killed Nontypeable Haemophilus influenzae Immunotherapeutic For The Prevention Of Acute Exacerbations Of Chronic Airway Disease.” International journal of chronic obstructive pulmonary disease (2019). PMID: 31695359 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management: Pharmacological Therapy
[17]
Leung JM, Tiew PY, Mac Aogáin M et al.. “The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD.” Respirology (Carlton, Vic.) (2017). PMID: 28342288 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[18]
Ritchie AI, Farne HA, Singanayagam A et al.. “Pathogenesis of Viral Infection in Exacerbations of Airway Disease.” Annals of the American Thoracic Society (2015). PMID: 26595727 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[19]
Sasaki T, Nakayama K, Yasuda H et al.. “A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD.” Therapeutic advances in respiratory disease (2011). PMID: 21285157 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[20]
Papaetis GS, Anastasakou E, Orphanidou D. “Chlamydophila pneumoniae infection and COPD: more evidence for lack of evidence?” European journal of internal medicine (2009). PMID: 19782917 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[21]
Cazzola M, Rogliani P, Curradi G. “Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view.” Respiratory medicine (2008). PMID: 18164190 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[22]
Hutchinson AF, Ghimire AK, Thompson MA et al.. “A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD.” Respiratory medicine (2007). PMID: 17822891 ↗
L3bCASE_CONTROLCited in: Etiology and Triggering Factors
[23]
Greenberg SB. “Rhinovirus and coronavirus infections.” Seminars in respiratory and critical care medicine (2007). PMID: 17458772 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[24]
Footitt J, Johnston SL. “Cough and viruses in airways disease: mechanisms.” Pulmonary pharmacology & therapeutics (2009). PMID: 19480062 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[25]
Black PN, McDonald CF. “Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease.” Postgraduate medical journal (2009). PMID: 19351641 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
[26]
Chen CYJ, Yew MS, Abisheganaden JA et al.. “Predictors of Influenza PCR Positivity in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.” International journal of chronic obstructive pulmonary disease (2022). PMID: 35023911 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup
[27]
Oliveira A, Quach S, Alsubheen S et al.. “Rapid access rehabilitation after exacerbations of COPD - A qualitative study.” Respiratory medicine (2021). PMID: 34260976 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes
[28]
Schneider CV, Strnad P. “SARS-CoV-2 infection in alpha1-antitrypsin deficiency.” Respiratory medicine (2021). PMID: 34010739 ↗
L5OTHERCited in: Etiology and Triggering Factors
[29]
Jang JG, Ahn JH, Jin HJ. “Incidence and Prognostic Factors of Respiratory Viral Infections in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease.” International journal of chronic obstructive pulmonary disease (2021). PMID: 33994783 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes
[30]
Nolen LD, Seeman S, Desnoyers C et al.. “Respiratory syncytial virus and influenza hospitalizations in Alaska native adults.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2020). PMID: 32334281 ↗
L5OTHERCited in: Etiology and Triggering Factors
[31]
Dauchy C, Bautin N, Nseir S et al.. “Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.” Indoor air (2018). PMID: 29082624 ↗
L5OTHERCited in: Etiology and Triggering Factors
[32]
Jabbour S, Fouhey D, Shepard S et al.. “Measuring the Impact of AI in the Diagnosis of Hospitalized Patients: A Randomized Clinical Vignette Survey Study.” JAMA (2023). PMID: 38112814 ↗
L1bRCTCited in: Diagnosis and Workup, Differential Diagnosis
[33]
Galindo-Filho VC, Alcoforado L, Rattes C et al.. “A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols.” Respiratory medicine (2019). PMID: 31170543 ↗
L1bRCTCited in: Diagnosis and Workup, Management: Pharmacological Therapy, Management: Respiratory Support
[34]
Furian M, Lichtblau M, Aeschbacher SS et al.. “Efficacy of Dexamethasone in Preventing Acute Mountain Sickness in COPD Patients: Randomized Trial.” Chest (2018). PMID: 29909285 ↗
L1bRCTCited in: Diagnosis and Workup, Management: Pharmacological Therapy, Prognosis and Long-term Outcomes
[35]
Daubin C, Valette X, Thiollière F et al.. “Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.” Intensive care medicine (2018). PMID: 29663044 ↗
L1bRCTCited in: Diagnosis and Workup, Management: Pharmacological Therapy
[36]
Jaeger D, Duchanois C, Duarte K et al.. “Performance of an ultrasound diagnostic algorithm for acute dyspneic patients in the emergency department: an EMERALD-US protocol.” BMJ open (2025). PMID: 40784781 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Differential Diagnosis
[37]
Jin J, Zhang H, Li D et al.. “Effectiveness of Xin Jia Xuan Bai Cheng Qi Decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol for a multicentre, randomised, controlled trial.” BMJ open (2019). PMID: 31784433 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[38]
Sehgal IS, Kalpakam H, Dhooria S et al.. “A Randomized Controlled Trial of Noninvasive Ventilation with Pressure Support Ventilation and Adaptive Support Ventilation in Acute Exacerbation of COPD: A Feasibility Study.” COPD (2019). PMID: 31161812 ↗
L1bRCTCited in: Diagnosis and Workup, Management: Respiratory Support, Prognosis and Long-term Outcomes
[39]
Li L, Wang L, Zhang L et al.. “Frailty and in-hospital mortality in older patients with acute exacerbation of COPD: A real-world prospective cohort study.” Respiratory medicine (2024). PMID: 38763445 ↗
L2bCOHORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[40]
Cortegiani A, Longhini F, Carlucci A et al.. “High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol for a noninferiority randomized clinical trial.” Trials (2019). PMID: 31331372 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management: Respiratory Support, Prognosis and Long-term Outcomes
[41]
Zhen G, Jing J, Fengsen L. “Traditional Chinese medicine classic herbal formula Xiaoqinglong decoction for acute exacerbation of chronic obstructive pulmonary disease: A systematic review protocol.” Medicine (2018). PMID: 30593152 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[42]
Hu WP, Lhamo T, Zhang FY et al.. “Predictors of acute cardiovascular events following acute exacerbation period for patients with COPD: a nested case-control study.” BMC cardiovascular disorders (2020). PMID: 33302869 ↗
L3bCASE_CONTROLCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[43]
Gloeckl R, Jones PW, Kroll D et al.. “Can Patient Education Lead the Way? Head-To-Head Comparison of EXACT and CERT for Early Recognition of Acute COPD Exacerbations.” Respirology (Carlton, Vic.) (2026). PMID: 41320645 ↗
L5OTHERCited in: Diagnosis and Workup
[44]
Pillai S, Lawrence M, Zaldua JC et al.. “Alterations in clot microstructure in acute exacerbations of COPD.” Respiratory research (2025). PMID: 41254616 ↗
L5OTHERCited in: Diagnosis and Workup
[45]
Hamza Yousef MS, Al Azizi HM, Fouad MM. “Point of care ultrasound as a bedside diagnostic tool in acute dyspnea patients in emergency department for timely management.” Respiratory medicine (2025). PMID: 41237919 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
[46]
Welch C, Bravo L, Gkoutos G et al.. “Establishing Predictors of Acute Sarcopenia: A Proof-Of-Concept Study Utilising Network Analysis.” Aging and disease (2024). PMID: 39012665 ↗
L5OTHERCited in: Diagnosis and Workup
[47]
Echevarria C, Steer J, Prasad A et al.. “Admission blood eosinophil count, inpatient death and death at 1 year in exacerbating patients with COPD.” Thorax (2023). PMID: 37487711 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Pharmacological Therapy
[48]
Zhang Y, Ren L, Sun J et al.. “Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.” International journal of chronic obstructive pulmonary disease (2021). PMID: 34522094 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[49]
Peng L, Han L, Li XN et al.. “The Predictive Value of microRNA-134 and microRNA-1233 for the Early Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Pulmonary Embolism.” International journal of chronic obstructive pulmonary disease (2020). PMID: 33116466 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
[50]
Karege G, Zekry D, Allali G et al.. “Gait speed is associated with death or readmission among patients surviving acute hypercapnic respiratory failure.” BMJ open respiratory research (2020). PMID: 32561512 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Respiratory Support, Prognosis and Long-term Outcomes
[51]
Miró Ò, Takagi K, Gayat E et al.. “CORT-AHF Study: Effect on Outcomes of Systemic Corticosteroid Therapy During Early Management Acute Heart Failure.” JACC. Heart failure (2019). PMID: 31521676 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Pharmacological Therapy, Prognosis and Long-term Outcomes
[52]
Pulido Herrero E, García Gutiérrez S, Antón Ladislao A et al.. “Chronic obstructive pulmonary disease assessment test: usefulness for monitoring recovery and predicting poor course of disease after exacerbations.” Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias (2019). PMID: 30656869 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
[53]
Suzuki S, Yoshihisa A, Sato Y et al.. “Clinical Significance of Get With the Guidelines-Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization.” Journal of the American Heart Association (2018). PMID: 30371158 ↗
L5OTHERCited in: Diagnosis and Workup
[54]
Ladjemi MZ, Martin C, Lecocq M et al.. “Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2019). PMID: 30339768 ↗
L5OTHERCited in: Diagnosis and Workup
[55]
Labaki WW, Xia M, Murray S et al.. “NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.” Respiratory medicine (2018). PMID: 29957287 ↗
L5OTHERCited in: Diagnosis and Workup
[56]
Oliveira A, Rodrigues J, Marques A. “Enhancing our understanding of computerised adventitious respiratory sounds in different COPD phases and healthy people.” Respiratory medicine (2018). PMID: 29724394 ↗
L5OTHERCited in: Diagnosis and Workup
[57]
Aleva FE, Voets LWLM, Simons SO et al.. “Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis.” Chest (2017). PMID: 27522956 ↗
L2aSR_OBSCited in: Differential Diagnosis
[58]
Domínguez-Rodríguez A, Hernandez-Vaquero D, Suero-Mendez C et al.. “Effects of MIdazolam versus MOrphine in acute cardiogenic pulmonary edema and chronic obstructive pulmonary disease: An analysis of MIMO trial.” The American journal of emergency medicine (2023). PMID: 37703629 ↗
L1bRCTCited in: Differential Diagnosis
[59]
Deutz NE, Matheson EM, Matarese LE et al.. “Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial.” Clinical nutrition (Edinburgh, Scotland) (2016). PMID: 26797412 ↗
L1bRCTCited in: Differential Diagnosis, Management: Pharmacological Therapy
[60]
Prosen G, Klemen P, Štrnad M et al.. “Combination of lung ultrasound (a comet-tail sign) and N-terminal pro-brain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting.” Critical care (London, England) (2011). PMID: 21492424 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis
[61]
Gulea C, Zakeri R, Quint JK. “Impact of chronic obstructive pulmonary disease on readmission after hospitalization for acute heart failure: A nationally representative US cohort study.” International journal of cardiology (2019). PMID: 31101544 ↗
L2bCOHORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes
[62]
Cao YQ, Dong LX, Cao J. “Pulmonary Embolism in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.” Chinese medical journal (2018). PMID: 29998894 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[63]
Neesse A, Jerrentrup A, Hoffmann S et al.. “Prehospital chest emergency sonography trial in Germany: a prospective study.” European journal of emergency medicine : official journal of the European Society for Emergency Medicine (2012). PMID: 21817908 ↗
L2bCOHORTCited in: Differential Diagnosis
[64]
Fu X, Zhong Y, Xu W et al.. “The prevalence and clinical features of pulmonary embolism in patients with AE-COPD: A meta-analysis and systematic review.” PloS one (2021). PMID: 34473738 ↗
L2aSR_OBSCited in: Differential Diagnosis
[65]
Ege MR, Guray U, Guray Y et al.. “Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers?” Herz (2012). PMID: 22699995 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis
[66]
Nakamura K, Alba GA, Scheske JA et al.. “A 57-Year-Old Man With Insidious Dyspnea and Nonpleuritic Chest and Back Pain.” Chest (2016). PMID: 27502992 ↗
L4CASE_REPORTCited in: Differential Diagnosis
[67]
Mantuani D, Nagdev A. “Three-view bedside ultrasound to differentiate acute decompensated heart failure from chronic obstructive pulmonary disease.” The American journal of emergency medicine (2013). PMID: 23380088 ↗
L4CASE_REPORTCited in: Differential Diagnosis
[68]
Bertoletti L, Couturaud F, Sanchez O et al.. “Pulmonary Embolism and Chronic Obstructive Pulmonary Disease.” Seminars in thrombosis and hemostasis (2023). PMID: 36108648 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[69]
Hüfner A, Dodt C. “[Ermergency diagnostics and therapeutic management of acute dyspnea].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2015). PMID: 26407960 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[70]
Hüfner A, Dodt C. “[Definition, primary examination and differential diagnostics in acute dyspnea].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2015). PMID: 26335293 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[71]
Farmakis IT, Valerio L, Barco S et al.. “Functional capacity and dyspnea during follow-up after acute pulmonary embolism.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 37652350 ↗
L5OTHERCited in: Differential Diagnosis
[72]
Cerullo M, Yang K, Joynt Maddox KE et al.. “Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries.” JAMA network open (2022). PMID: 35486398 ↗
L5OTHERCited in: Differential Diagnosis
[73]
Beltaief K, Msolli MA, Zorgati A et al.. “Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation: A Randomized Double-blind Controlled Trial.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2019). PMID: 30156361 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[74]
Ding Z, Li X, Lu Y et al.. “A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease.” Respiratory medicine (2016). PMID: 27888990 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[75]
Wang JX, Zhang SM, Li XH et al.. “Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2016). PMID: 27155210 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[76]
Gold DR, Litonjua AA, Carey VJ et al.. “Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults.” Contemporary clinical trials (2016). PMID: 26784651 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[77]
Geiger-Brown J, Lindberg S, Krachman S et al.. “Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease.” International journal of chronic obstructive pulmonary disease (2015). PMID: 25759571 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[78]
Rabe KF, Fabbri LM, Israel E et al.. “Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.” The Lancet. Respiratory medicine (2014). PMID: 24461901 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[79]
Rogliani P, Ora J, Ciaprini C et al.. “Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD.” Respiratory medicine (2014). PMID: 24238769 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[80]
Anzueto A, Niewoehner DE, Leimer I et al.. “A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.” Respiratory medicine (2013). PMID: 23969305 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[81]
Leuppi JD, Schuetz P, Bingisser R et al.. “Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.” JAMA (2013). PMID: 23695200 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[82]
Torres-Sánchez I, Valenza MC, Cabrera-Martos I et al.. “Effects of an Exercise Intervention in Frail Older Patients with Chronic Obstructive Pulmonary Disease Hospitalized due to an Exacerbation: A Randomized Controlled Trial.” COPD (2017). PMID: 27715322 ↗
L1bRCTCited in: Management: Pharmacological Therapy, Management: Respiratory Support
[83]
Rohde GG, Koch A, Welte T. “Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD--the ABACOPD study.” BMC pulmonary medicine (2015). PMID: 25623589 ↗
L1bRCTCited in: Management: Pharmacological Therapy, Management: Respiratory Support
[84]
Segreti A, Fiori E, Calzetta L et al.. “The effect of indacaterol during an acute exacerbation of COPD.” Pulmonary pharmacology & therapeutics (2013). PMID: 23578980 ↗
L1bRCTCited in: Management: Pharmacological Therapy
[85]
Postma DS, Anzueto AR, Jenkins C et al.. “Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristics.” Respiratory medicine (2013). PMID: 23953956 ↗
L2aSR_OBSCited in: Management: Pharmacological Therapy
[86]
Vermeersch K, Gabrovska M, Deslypere G et al.. “The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.” International journal of chronic obstructive pulmonary disease (2016). PMID: 27099485 ↗
L5OTHERCited in: Management: Pharmacological Therapy
[87]
Lopardo G, Pensotti C, Scapellato P et al.. “[Inter-society consensus for the management of respiratory infections: acute bronchitis and chronic obstructive pulmonary disease].” Medicina (2013). PMID: 23570768 ↗
L1cGUIDELINECited in: Management: Pharmacological Therapy, Guidelines and Resources
[88]
Yang L, Li M, Shu J et al.. “A Risk Prediction Model for Prolonged Length of Stay in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective Study of 225 Patients in a Single Center in Kunming, China.” Medical science monitor : international medical journal of experimental and clinical research (2022). PMID: 35136009 ↗
L2bCOHORTCited in: Management: Pharmacological Therapy
[89]
Walters JA, Tan DJ, White CJ et al.. “Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2014). PMID: 25178099 ↗
L2aSR_OBSCited in: Management: Pharmacological Therapy
[90]
Whittaker Brown SA, Braman S. “Recent Advances in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.” The Medical clinics of North America (2020). PMID: 32505256 ↗
L5REVIEW_NARRATIVECited in: Management: Pharmacological Therapy, Management: Respiratory Support
[91]
Komagamine J. “Prevalence of potentially inappropriate medications at admission and discharge among hospitalised elderly patients with acute medical illness at a single centre in Japan: a retrospective cross-sectional study.” BMJ open (2018). PMID: 30030316 ↗
L5OTHERCited in: Management: Pharmacological Therapy
[92]
Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM et al.. “Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease.” Respiratory medicine (2018). PMID: 29724384 ↗
L5OTHERCited in: Management: Pharmacological Therapy
[93]
Su VY, Yang KY, Yang YH et al.. “Use of ICS/LABA Combinations or LAMA Is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma.” The journal of allergy and clinical immunology. In practice (2018). PMID: 29432960 ↗
L5OTHERCited in: Management: Pharmacological Therapy
[94]
Kelly AM, Holdgate A, Keijzers G et al.. “Epidemiology, treatment, disposition and outcome of patients with acute exacerbation of COPD presenting to emergency departments in Australia and South East Asia: An AANZDEM study.” Respirology (Carlton, Vic.) (2018). PMID: 29394524 ↗
L5OTHERCited in: Management: Pharmacological Therapy, Management: Respiratory Support
[95]
Ergan B, Ergün R. “Impact of anemia on short-term survival in severe COPD exacerbations: a cohort study.” International journal of chronic obstructive pulmonary disease (2016). PMID: 27536089 ↗
L2bCOHORTCited in: Management: Respiratory Support
[96]
Corrêa TD, Sanches PR, de Morais LC et al.. “Performance of noninvasive ventilation in acute respiratory failure in critically ill patients: a prospective, observational, cohort study.” BMC pulmonary medicine (2015). PMID: 26559350 ↗
L2bCOHORTCited in: Management: Respiratory Support
[97]
Jayadev A, Stone R, Steiner MC et al.. “Time to NIV and mortality in AECOPD hospital admissions: an observational study into real world insights from National COPD Audits.” BMJ open respiratory research (2019). PMID: 31423314 ↗
L5OTHERCited in: Management: Respiratory Support
[98]
Comellini V, Pacilli AMG, Nava S. “Benefits of non-invasive ventilation in acute hypercapnic respiratory failure.” Respirology (Carlton, Vic.) (2019). PMID: 30636373 ↗
L5REVIEW_NARRATIVECited in: Management: Respiratory Support
[99]
Miró Ò, Martínez G, Masip J et al.. “Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry.” European journal of internal medicine (2018). PMID: 29572091 ↗
L5OTHERCited in: Management: Respiratory Support
[100]
Parker K, Perikala V, Aminazad A et al.. “Models of care for non-invasive ventilation in the Acute COPD Comparison of three Tertiary hospitals (ACT3) study.” Respirology (Carlton, Vic.) (2018). PMID: 29224257 ↗
L5OTHERCited in: Management: Respiratory Support
[101]
Poon T, Paris DG, Aitken SL et al.. “Extended Versus Short-Course Corticosteroid Taper Regimens in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Critically Ill Patients.” Journal of intensive care medicine (2020). PMID: 29161935 ↗
L5OTHERCited in: Management: Respiratory Support
[102]
Lemyze M, Bury Q, Guiot A et al.. “Delayed but successful response to noninvasive ventilation in COPD patients with acute hypercapnic respiratory failure.” International journal of chronic obstructive pulmonary disease (2017). PMID: 28579772 ↗
L5OTHERCited in: Management: Respiratory Support
[103]
Song Y, Chen R, Zhan Q et al.. “The optimum timing to wean invasive ventilation for patients with AECOPD or COPD with pulmonary infection.” International journal of chronic obstructive pulmonary disease (2016). PMID: 27042042 ↗
L5REVIEW_NARRATIVECited in: Management: Respiratory Support
[104]
Pisani L, Corcione N, Nava S. “Management of acute hypercapnic respiratory failure.” Current opinion in critical care (2016). PMID: 26627537 ↗
L5REVIEW_NARRATIVECited in: Management: Respiratory Support
[105]
Fan L, Zhao Q, Liu Y et al.. “Semiquantitative cough strength score and associated outcomes in noninvasive positive pressure ventilation patients with acute exacerbation of chronic obstructive pulmonary disease.” Respiratory medicine (2014). PMID: 25459451 ↗
L5OTHERCited in: Management: Respiratory Support
[106]
Brill SE, Wedzicha JA. “Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.” International journal of chronic obstructive pulmonary disease (2014). PMID: 25404854 ↗
L5REVIEW_NARRATIVECited in: Management: Respiratory Support
[107]
Ongel EA, Karakurt Z, Salturk C et al.. “How do COPD comorbidities affect ICU outcomes?” International journal of chronic obstructive pulmonary disease (2014). PMID: 25378919 ↗
L5OTHERCited in: Management: Respiratory Support
[108]
Lindenauer PK, Stefan MS, Shieh MS et al.. “Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease.” JAMA internal medicine (2014). PMID: 25347545 ↗
L5OTHERCited in: Management: Respiratory Support
[109]
Park MJ, Rhee CK, Kim YH et al.. “Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study.” Current medical research and opinion (2017). PMID: 28277874 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes
[110]
Mir T, Uddin M, Khalil A et al.. “Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population.” Respiratory medicine (2022). PMID: 34959147 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes
[111]
Hoffman GJ, Yakusheva O. “Association Between Financial Incentives in Medicare's Hospital Readmissions Reduction Program and Hospital Readmission Performance.” JAMA network open (2020). PMID: 32242906 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes
[112]
Spannella F, Giulietti F, Cocci G et al.. “Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Oldest Adults: Predictors of In-Hospital Mortality and Need for Post-acute Care.” Journal of the American Medical Directors Association (2019). PMID: 30826270 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes
[113]
Chen W, Qing-yuan Z. “[Guideline for mechanical ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease (2007)].” Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue (2007). PMID: 17767816 ↗
L1cGUIDELINECited in: Guidelines and Resources
[114]
Singer D, Wang Y, La EM et al.. “Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41432364 ↗
L3bCited in: Etiology and Triggering Factors
[115]
Nirappil FJ, Maheshwari A, Andrews J et al.. “Characteristics and outcomes of HIV-1-infected patients with acute respiratory distress syndrome.” Journal of critical care (2014). PMID: 25466320 ↗
L3bCited in: Etiology and Triggering Factors
[116]
Hui DS, Ip M, Ling T et al.. “A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis.” Respirology (Carlton, Vic.) (2011). PMID: 21299688 ↗
L3bCited in: Etiology and Triggering Factors
[117]
Nseir S, Cavestri B, Di Pompeo C et al.. “Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease.” Respiration; international review of thoracic diseases (2008). PMID: 18547944 ↗
L2bCited in: Etiology and Triggering Factors
[118]
Homma T, Kawahara T, Mikuni H et al.. “Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.” International archives of allergy and immunology (2019). PMID: 30759444 ↗
L2bCited in: Etiology and Triggering Factors
[119]
Ohteru Y, Kakugawa T, Kakugawa M et al.. “Impact of the COVID-19 pandemic on acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study in Japan.” Respiratory investigation (2025). PMID: 41253080 ↗
L3bCited in: Etiology and Triggering Factors
[120]
Boixeda R, Bacca S, Elias L et al.. “Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD.” Archivos de bronconeumologia (2014). PMID: 25443591 ↗
L2bCited in: Etiology and Triggering Factors
[121]
Piñol-Ripoll G, de la Puerta I, Santos S et al.. “Chronic bronchitis and acute infections as new risk factors for ischemic stroke and the lack of protection offered by the influenza vaccination.” Cerebrovascular diseases (Basel, Switzerland) (2008). PMID: 18728360 ↗
L3bCited in: Etiology and Triggering Factors
[122]
Lapanan C, Schreiber AF, Wongtirawit N et al.. “The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover study.” Pulmonology (2026). PMID: 42345563 ↗
L1bCited in: Diagnosis and Workup
[123]
Brendel JH, Andersen LW, Skaarup SH et al.. “Prehospital Use of Non-Invasive Ventilation for Acute Respiratory Failure due to Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Randomised Trial.” Acta anaesthesiologica Scandinavica (2026). PMID: 42219224 ↗
L1bCited in: Diagnosis and Workup
[124]
Fisher KA, Stefan MS, Darling C et al.. “Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study.” Chest (2015). PMID: 25188234 ↗
L3bCited in: Differential Diagnosis
[125]
Parissis JT, Andreoli C, Kadoglou N et al.. “Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.” Clinical research in cardiology : official journal of the German Cardiac Society (2014). PMID: 24718849 ↗
L4Cited in: Differential Diagnosis
[126]
Stefan MS, Rothberg MB, Priya A et al.. “Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.” Thorax (2012). PMID: 22941975 ↗
L3bCited in: Differential Diagnosis
[127]
Ovchinnikova ES, Schmitter D, Vegter EL et al.. “Signature of circulating microRNAs in patients with acute heart failure.” European journal of heart failure (2015). PMID: 26345695 ↗
L3bCited in: Differential Diagnosis
[128]
Pizzini A, Lunger F, Sahanic A et al.. “Diagnostic and Prognostic Value of Inflammatory Parameters Including Neopterin in the Setting of Pneumonia, COPD, and Acute Exacerbations.” COPD (2017). PMID: 28548632 ↗
L3bCited in: Differential Diagnosis
[129]
Bahloul M, Chaari A, Tounsi A et al.. “Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases.” The clinical respiratory journal (2014). PMID: 24612880 ↗
L3bCited in: Differential Diagnosis
[130]
Hanania NA, Calverley PM, Dransfield MT et al.. “Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.” Respiratory medicine (2013). PMID: 24120253 ↗
L1bCited in: Management: Pharmacological Therapy
[131]
Ozsancak Ugurlu A, Habesoglu MA. “Epidemiology of NIV for Acute Respiratory Failure in COPD Patients: Results from the International Surveys vs. the "Real World".” COPD (2017). PMID: 28636452 ↗
L1bCited in: Management: Respiratory Support
[132]
Fiorino S, Bacchi-Reggiani L, Detotto E et al.. “Efficacy of non-invasive mechanical ventilation in the general ward in patients with chronic obstructive pulmonary disease admitted for hypercapnic acute respiratory failure and pH < 7.35: a feasibility pilot study.” Internal medicine journal (2015). PMID: 25684643 ↗
L4Cited in: Management: Respiratory Support
[133]
Loh CH, Peters SP, Lovings TM et al.. “Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.” Annals of the American Thoracic Society (2017). PMID: 28406710 ↗
L3bCited in: Prognosis and Long-term Outcomes